Abetimus

From WikiProjectMed
Jump to navigation Jump to search
Abetimus sodium
Abetimus.svg
Clinical data
Trade namesRiquent
ATC code
Identifiers
CAS Number
PubChem SID
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC1632H1944N610Na156O970P156S4
Molar mass54171.35 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Abetimus (trade name Riquent) is an immunosuppressant.[1] It is a synthetic biological called a tolerogen. It is made of four double-stranded oligodeoxyribonucleotides that are attached to a carrier platform and are designed to block specific B-cell anti double stranded DNA antibodies.[2] It may also complex anti dsDNA antibodies together, therefore disabling them. This way abetimus was supposed to help treat systemic lupus erythematosus and specifically lupus nephritis.

It was developed by La Jolla Pharmaceutical, who applied for marketing authorisations in the mid-2000s, but the drug was never marketed in the US or in Europe.[3][4]

References

  1. ^ "Abetimus: Abetimus sodium, LJP 394". BioDrugs. Springer Nature Switzerland AG. 17 (3): 212–5. 2003. doi:10.2165/00063030-200317030-00009. PMID 12749759. S2CID 19896886.
  2. ^ Wallace DJ (January 2001). "Clinical and pharmacological experience with LJP-394". Expert Opinion on Investigational Drugs. Informa. 10 (1): 111–7. doi:10.1517/13543784.10.1.111. PMID 11116284. S2CID 43518002.
  3. ^ "Riquent Approval Status". Drugs.com. Retrieved 7 January 2017.
  4. ^ "Riquent". European Medicines Agency. Retrieved 7 January 2017.